Neurochemical Mechanisms in Affective Disorders

Affective disorders such as major depressive disorder and bipolar disorder arise from dysregulation within central neurotransmitter systems, notably those mediating serotonin, dopamine and noradrenaline signalling. Altered synthesis, release and reuptake of monoamines, together with shifts in receptor density and downstream metabolite levels, contribute to mood instability, anhedonia and anxiety. Cerebrospinal fluid sampling has revealed trait and state markers, including fluctuations in homovanillic acid and 5-hydroxyindoleacetic acid, while advanced chromatographic and imaging methods have mapped concentration gradients and receptor binding in key limbic regions. These neurochemical signatures underpin efforts to stratify subtypes, predict treatment response and develop targeted therapeutics. Integrative models now emphasise interactions between synaptic signalling, neuroendocrine rhythms and inflammatory mediators, highlighting the importance of precision approaches to diagnosis and intervention on a global scale.

Research from Nature Portfolio

A foundational cerebrospinal fluid study identified significantly reduced ethanolamine concentrations in individuals with major depressive disorder compared with controls, defining a state-dependent biomarker linked to symptom severity. Lower ethanolamine correlated with elevated scores for somatic anxiety and overall depression, suggesting a role for phospholipid precursors in mood regulation and offering a potential avenue for personalised monitoring of treatment effects.

Neurochemical Mechanisms in Affective Disorders publication trend

The graph below shows the total number of articles in neurochemical mechanisms in affective disorders across all publications each year (not limited to Nature Index journals).

Technical terms

Monoamines: Biogenic amine neurotransmitters including serotonin, dopamine and noradrenaline involved in mood regulation.

Cerebrospinal fluid (CSF): Clear fluid in brain and spinal cord compartments used to assess central neurochemical biomarkers.

Homovanillic acid (HVA): Principal end-product of dopamine metabolism, reflecting dopaminergic activity.

5-Hydroxyindoleacetic acid (5-HIAA): Main metabolite of serotonin, indicating serotonergic turnover.

Ethanolamine: Biogenic amine precursor in phospholipid synthesis, emerging as a potential biomarker in depressive states.

References

1. Concentration gradients of monoamines, their precursors and metabolites in serial lumbar cerebrospinal fluid of neurologically healthy patients determined with a novel LC–MS/MS technique. Fluids and Barriers of the CNS (2023).
2. Reduced cerebrospinal fluid ethanolamine concentration in major depressive disorder. Scientific Reports (2015).
3. Altered brain dopamine metabolism is a trait marker for bipolar disorder. Biomarkers in Neuropsychiatry (2023).
4. Hostility in medication-resistant major depression and comorbid generalized anxiety disorder is related to increased hippocampal–amygdala 5-HT2A receptor density. European Archives of Psychiatry and Clinical Neuroscience (2021).